Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
5.01
+0.48 (10.60%)
At close: Feb 27, 2026, 4:00 PM EST
4.910
-0.100 (-2.00%)
After-hours: Feb 27, 2026, 7:57 PM EST
Rocket Pharmaceuticals Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Rocket Pharmaceuticals stock have an average target of 30.42, with a low estimate of 2.50 and a high estimate of 263. The average target predicts an increase of 507.19% from the current stock price of 5.01.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Rocket Pharmaceuticals stock from 14 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 5 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $8 → $10 | Buy | Maintains | $8 → $10 | +99.60% | Feb 27, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $10 → $8 | Strong Buy | Maintains | $10 → $8 | +59.68% | Nov 18, 2025 |
| JP Morgan | JP Morgan | Buy → Sell Downgrades $261 → $263 | Buy → Sell | Downgrades | $261 → $263 | +5,149.50% | Nov 18, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +119.56% | Oct 14, 2025 |
| Leerink Partners | Leerink Partners | Hold Maintains $9 → $7 | Hold | Maintains | $9 → $7 | +39.72% | Oct 3, 2025 |
Financial Forecast
Revenue This Year
18.37M
Revenue Next Year
9.39M
from 18.37M
Decreased by -48.89%
EPS This Year
-1.54
from -2.01
EPS Next Year
-1.32
from -1.54
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 150.2M | 26.3M | |||
| Avg | 18.4M | 9.4M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 43.2% | |||
| Avg | - | -48.9% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.06 | -0.78 | |||
| Avg | -1.54 | -1.32 | |||
| Low | -1.79 | -1.97 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.